Annexon Posts 28c Q2 Loss, Cash Runway in Focus
ANNX has more than doubled off its 52-week low of $2.03 on light trading volume (0.3× avg).
Summary
Annexon reported a Q2 loss of 28 cents per share, a key data point for a pre-revenue biotech burning cash. The company recently drew $50 million from a new $200 million credit facility and has an active $150 million ATM program, so the loss rate directly impacts dilution risk. This follows positive early data from the FORWARD study and the completion of enrollment in the pivotal Phase 3 ARCHER II trial, raising the stakes for upcoming catalysts. The Q2 filing will clarify whether the cash runway into H2 2027 remains intact.
At the time of this announcement, ANNX was trading at $5.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $874.9M. The 52-week trading range was $2.03 to $7.18. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.